IL6 and metabolic dysfunction-associated steatotic liver disease: Compared with controls, patients with MASLD exhibited a more adverse metabolic and inflammatory profile, characterized by higher atherogenic lipids, elevated IL-6 and IL-10 concentrations, and increased liver stiffness, while TNF-α levels remained comparable between groups.